Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01309698
First received: March 4, 2011
Last updated: October 10, 2011
Last verified: October 2011
  Purpose

This study will evaluate the effect of voglibose on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.


Condition Intervention Phase
Type 2 Diabetes
Drug: Vildagliptin (LAF237)
Drug: Voglibose
Drug: Vildagliptin and Voglibose
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: An Open-label, Randomized and Crossover Study to Assess the Effect of Co-administration of Vildagliptin and Voglibose on the Steady-state Pharmacokinetics / Pharmacodynamics in Japanese Patients With Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Pharmacokinetics of vildagliptin [ Time Frame: Up to 12 hours post-dose ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pharmacodynamic parameters (dipeptidyl peptidase IV (DPP-4) activity, glucagon-like peptide-1(GLP-1), glucose, insulin, glucagon) [ Time Frame: Up to 4 hours or 12 hours post-dose ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: February 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Sequence 1 Drug: Vildagliptin (LAF237) Drug: Voglibose Drug: Vildagliptin and Voglibose
Experimental: Treatment Sequence 2 Drug: Vildagliptin (LAF237) Drug: Voglibose Drug: Vildagliptin and Voglibose
Experimental: Treatment Sequence 3 Drug: Vildagliptin (LAF237) Drug: Voglibose Drug: Vildagliptin and Voglibose
Experimental: Treatment Sequence 4 Drug: Vildagliptin (LAF237) Drug: Voglibose Drug: Vildagliptin and Voglibose
Experimental: Treatment Sequence 5 Drug: Vildagliptin (LAF237) Drug: Voglibose Drug: Vildagliptin and Voglibose
Experimental: Treatment Sequence 6 Drug: Vildagliptin (LAF237) Drug: Voglibose Drug: Vildagliptin and Voglibose

  Eligibility

Ages Eligible for Study:   20 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diabetic patients with inadequately controlled on diet therapy and exercise therapy (HbA1c in the range 6.5 to 10.0% inclusive by NGSP)

Exclusion Criteria:

  • Fasting plasma glucose ≥ 270 mg/dL A history of Type 1 diabetes or secondary forms of diabetes Treatment of anti-diabetic agents including GLP-1 analogues within 8 weeks or insulin within 6 months prior to screening Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01309698

Locations
Japan
Novartis Investigative Site
Tokyo, Japan
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01309698     History of Changes
Other Study ID Numbers: CLAF237A1103
Study First Received: March 4, 2011
Last Updated: October 10, 2011
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Novartis:
Drug interaction

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Vildagliptin
Voglibose
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors

ClinicalTrials.gov processed this record on October 20, 2014